Compass Therapeutics
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact
A Novel Class of NK-Cell Engagers Targeting NKp30
A Novel Class of NK-Cell Engagers Targeting NKp30
Post navigation
Previous Post
Previous
CTX-471, a novel agonistic antibody targeting CD137, eradicates very large tumors by selectively reprogramming the tumor microenvironment without causing hepatic toxicity
Next Post
Next
Preclinical characterization of NKp30xBCMA, a novel class of NK‐Cell Engagers
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact